Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,211 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06431893Enrolling by invitationPhase 3
Long-term study of pegtibatinase for classical homocystinuria
This trial is a long-term follow-up study examining the safety and effectiveness of pegtibatinase for people with classical homocystinuria (HCU). It is open to those who have recently taken part in or finished the HARMONY or COMPOSE studies.
Phoenix, ArizonaAges 5–65 - NCT06381856Enrolling by invitation
Helping autistic kids take part in their care
This study tests a way to help autistic children and teenagers, who do not have an intellectual disability, get more involved in their own habilitation (a process that helps them build skills and live more independently).
Örebro, Örebro CountyAges 7–17 - NCT06369974Enrolling by invitationPhase 1/Phase 2
Experimental ASO treatment for TUBB4A-related leukodystrophy
This trial tests a single patient's response to an experimental genetic treatment (called an ASO) for a rare brain disease caused by changes in the TUBB4A gene. The goal is to see if the treatment can improve symptoms related to the condition H-ABC.
Boston, MassachusettsAges 4 years+ - NCT06363760Enrolling by invitation
Long-term follow-up after EDIT-301 gene therapy
This long-term follow-up study monitors people with sickle cell disease or transfusion-dependent beta-thalassemia who have already received the gene-editing therapy EDIT-301. It helps researchers understand how safe and effective the treatment is over time.
Oakland, CaliforniaAges 12–50 - NCT06312189Enrolling by invitationPhase 3
Long-term safety study of valbenazine for Huntington's chorea in Canada
This study is for people in Canada who have already been taking valbenazine for Huntington's chorea in a previous study (NBI-98854-HD3006). It tests the long-term safety of the medicine and continues for up to 156 weeks.
Vancouver, British ColumbiaAges 18 years+ - NCT06281457Enrolling by invitation
Visual attention study for healthy adults
This study tests how your brain pays attention to visual features like color or motion. You will do simple computer tasks while we measure your brain activity. It helps us understand normal vision.
Santa Barbara, CaliforniaAges 18–55 - NCT06275620Enrolling by invitationPhase 2
Testing a gene therapy for X-linked retinitis pigmentosa in males
This trial tests two doses of a gene therapy (AGTC-501) in males who already had one eye treated with a similar gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. The goal is to see if the treatment is safe and can help preserve or improve vision.
Jacksonville, FloridaAges 12 years+ - NCT06270719Enrolling by invitation
Comparing ELEVIDYS to standard care for Duchenne muscular dystrophy
This study compares the gene therapy ELEVIDYS (delandistrogene moxeparvovec) to usual treatments for people with Duchenne muscular dystrophy (DMD). It helps researchers understand how well ELEVIDYS works over time in real-world settings.
Little Rock, ArkansasAges 4 years+ - NCT06112327Enrolling by invitation
Long-term follow-up for a gene editing heart therapy
This study follows people who already received an experimental gene editing treatment for cardiovascular disease in a prior Verve trial. The goal is to monitor their health and any long-term effects over time.
AucklandAges 18 years+ - NCT06075537Enrolling by invitationPhase 2/Phase 3
Long-term safety study of a MPS II treatment
This study is for people with MPS II (Hunter syndrome) who have already completed a previous Denali study. It will test a drug called tividenofusp alfa (DNL310) over a longer period to see how safe it is and how well it works.
Oakland, CaliforniaAges Up to 18 years - NCT06066580Enrolling by invitationPhase 2
Long-term sevasemten study for Becker muscular dystrophy
This trial offers continued treatment with sevasemten (EDG-5506) for people with Becker muscular dystrophy who already completed a previous study of this drug. It tests the long-term safety and effects of taking sevasemten over more time.
Little Rock, ArkansasAges Any age - NCT06018389Enrolling by invitation
Preventing risky drinking in Danish high schools
This trial tests a program called 'Our Choice' to help prevent risky drinking among Danish high school students. It is for students and staff at 16 specific high schools starting in August 2023.
AarhusAges 15 years+ - NCT05988996Enrolling by invitation
Peer support groups for NICU families
This trial is testing a peer support group program for parents of babies in the NICU. It aims to help families feel supported and connected during a stressful time.
Portland, OregonAges 18–70 - NCT05967351Enrolling by invitationPhase 3
Long-term follow-up for Duchenne patients treated before
This study checks how people with Duchenne muscular dystrophy are doing long-term after receiving delandistrogene moxeparvovec (SRP-9001) in an earlier trial. It helps researchers understand the long-term safety and effects of that treatment.
Little Rock, ArkansasAges Any age - NCT05844449Enrolling by invitationPhase 3
Check long-term safety and effectiveness of CF medicines
This Phase 3 study looks at how well and how safely Vanzacaftor/Tezacaftor/Deutivacaftor works over the long term in people with cystic fibrosis who already took the study medicine before. It may help confirm the best long-term plan and spot important safety issues.
Orange, CaliforniaAges 1 year+ - NCT05735483Enrolling by invitationPhase 3
Long-term lebrikizumab study for moderate to severe eczema
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
Birmingham, AlabamaAges 6 months–18 years - NCT05520983Enrolling by invitation
Behavior program study for teens with learning or thinking differences
This study is testing a “behavioral health” treatment plan designed for teens who have intellectual and/or developmental disabilities. It may help identify which treatment approach works best for different youth needs.
Chicago, IllinoisAges 13–20 - NCT05481827Enrolling by invitationPhase 2
Safety follow-up for GT005 in geographic eye damage
This study checks the long-term safety of GT005, a treatment you received in an earlier study, for geographic atrophy related to age-related macular degeneration. It mainly asks you to come to follow-up visits and confirm how you are doing over time.
Poway, CaliforniaAges 55 years+ - NCT05146830Enrolling by invitation
Long-term follow-up for people previously treated for cystinosis
This study checks how people with cystinosis are doing long-term after finishing an earlier study medicine called CTNS-RD-04. It may help researchers understand the lasting effects and safety of that treatment over time.
La Jolla, CaliforniaAges 14–50 - NCT05127954Enrolling by invitationPhase 3
Long-term migraine tablet study for kids and teens ages 6–17
This study follows kids and teens who already took part in an earlier migraine medication study to check long-term safety and comfort with oral ubrogepant tablets. It may help families understand whether this migraine tablet is safe to keep using over time.
Huntsville, AlabamaAges 6–17 - NCT05049668Enrolling by invitation
Long-term follow-up for people from the RACE study
This study checks on people who took part in the earlier RACE trial and collected long-term health information. It helps researchers understand how the treatments given in that trial affect patients over time.
ParisAges Any age - NCT05041309Enrolling by invitation
Long-term follow-up after a Kite gene-cell infusion
This study checks on people long after they received a gene-modified cell infusion in a Kite-sponsored study. It helps researchers understand how treatments work over time and watch for any long-term effects.
Gilbert, ArizonaAges Any age - NCT04880876Enrolling by invitationPhase 3
Oral IBS-D medicine trial for kids and teens
This trial tests whether an oral medicine (eluxadoline) can help children and teens with IBS-D, a condition that causes stomach pain and frequent loose stools. It’s a Phase 3 study, meaning it’s designed to confirm benefits and safety.
Corona, CaliforniaAges 6–17 - NCT04243356Enrolling by invitation
ICU nurse involvement in a post-ICU follow-up clinic
This study looks at whether having ICU nurses actively involved in a follow-up clinic after ICU discharge improves patients’ recovery and follow-up care. It focuses on patients who were cared for in the ICU and the registered nurses who cared for them.
Ann Arbor, MichiganAges 18 years+
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,211 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.